{"public_id":"cl_9eec8b308cb6044e91bf4231b254811a","status":"active","superseded_by_public_id":null,"corpus_id":235887814,"text":"Following aaPRP administration, C-reactive protein (CRP) values decreased significantly while the lymphocyte-to-CRP ratio (LCR) and neutrophil-lymphocyte ratio (NLR) slightly increased.","confidence":0.85,"paper":{"corpus_id":235887814,"title":"Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients","url":"https://sah.borca.ai/papers/235887814"},"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.85,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_2ec40f50380d06c91364993c7c9e3bc6","name":"C-reactive protein (CRP)","description":"A blood inflammatory marker measured as a secondary outcome in this trial.","types":["biomarker"],"url":"https://sah.borca.ai/concepts/co_2ec40f50380d06c91364993c7c9e3bc6"},{"public_id":"co_6b764b343073c5812630f967a3bd74ab","name":"neutrophil-lymphocyte ratio (NLR)","description":"A ratio of neutrophil to lymphocyte counts used as a secondary outcome marker of inflammation in this trial.","types":["biomarker"],"url":"https://sah.borca.ai/concepts/co_6b764b343073c5812630f967a3bd74ab"},{"public_id":"co_af493fac30d35b95f67b8510340a372e","name":"lymphocyte-to-CRP ratio (LCR)","description":"A ratio of lymphocyte count to CRP level used as a secondary outcome marker in this trial.","types":["biomarker"],"url":"https://sah.borca.ai/concepts/co_af493fac30d35b95f67b8510340a372e"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_9eec8b308cb6044e91bf4231b254811a"}